A study of refractory B-ALL reported half (6/11) patients developed skin GVHD grade 2 and one patient developed liver GVHD grade 2, after receiving allogeneic donor-derived CD-19 CAR T treatment (90). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.